Skip to Content

Essity AB Class B

ESSITY B: XSTO (SWE)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
SEK 115.00GfgnQwzxcpwzf

Essity Earnings: Commoditized Consumer Tissue Business Is Hindering Margin Improvement

No-moat Essity’s second-quarter results disappointed investors, with the share price falling by around 10% in early trading. The adjusted EBIT of SEK 4.4 billion reported for the second quarter was below FactSet consensus of SEK 4.8 billion, hit by salary inflation and higher marketing costs in the consumer goods segment. Our full-year forecast was already lower than consensus; therefore, the update does not affect our fair value estimate of SEK 260. We view shares as fairly valued at this time.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of ESSITY B so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center